Literature DB >> 34671577

Recurrence of Graves' Disease (a Th1-type Cytokine Disease) Following SARS-CoV-2 mRNA Vaccine Administration: A Simple Coincidence?

Guillaume Pierman1, Etienne Delgrange1, Corinne Jonas1.   

Abstract

Graves' disease is the most frequent cause of hyperthyroidism in young women. This auto-immune disease is due to the production of class 1 IgG stimulating the TSH receptor. These antibodies are produced secondary to a Th1 immune response in which interferon gamma plays a key role. Vaccination is ongoing worldwide against SARS-CoV-2 and some of the vaccines include mRNA which seems to stimulate the Th1 immune response. Here, we report a case of recurrence of hyperthyroidism due to Graves' disease following mRNA vaccination and discuss the possible implicated mechanism. This observation argues for a systematic study of a population of patients with previous Graves' disease in order to assess the risk of recurrence following vaccination. LEARNING POINTS: Graves' disease is a Th1-mediated immune disease in which interferon gamma plays a key role.The recurrence of hyperthyroidism due to Grave's disease should be monitored in patients exposed to risk factors. © EFIM 2021.

Entities:  

Keywords:  Graves’ disease; Hyperthyroidism; SARS-CoV-2; vaccine

Year:  2021        PMID： 34671577      PMCID： PMC8523378          DOI： 10.12890/2021_002807

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN： 2284-2594


  5 in total

1.  Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease.

Authors:  Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Endocrinol Metab       Date:  2014-09-11       Impact factor: 5.958

2.  Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.

Authors:  Erin Y Liu; Leah M Smith; Anne K Ellis; Heather Whitaker; Barbara Law; Jeffrey C Kwong; Paddy Farrington; Linda E Lévesque
Journal:  CMAJ       Date:  2018-05-28       Impact factor: 8.262

3.  Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

Authors:  A J Coles; M Wing; S Smith; F Coraddu; S Greer; C Taylor; A Weetman; G Hale; V K Chatterjee; H Waldmann; A Compston
Journal:  Lancet       Date:  1999-11-13       Impact factor: 79.321

4.  Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants.

Authors:  Olga Vera-Lastra; Alberto Ordinola Navarro; Maria Pilar Cruz Domiguez; Gabriela Medina; Tania Ivonne Sánchez Valadez; Luis J Jara
Journal:  Thyroid       Date:  2021-05-03       Impact factor: 6.568

5.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.

Authors:  Ugur Sahin; Alexander Muik; Evelyna Derhovanessian; Isabel Vogler; Lena M Kranz; Mathias Vormehr; Alina Baum; Kristen Pascal; Jasmin Quandt; Daniel Maurus; Sebastian Brachtendorf; Verena Lörks; Julian Sikorski; Rolf Hilker; Dirk Becker; Ann-Kathrin Eller; Jan Grützner; Carsten Boesler; Corinna Rosenbaum; Marie-Cristine Kühnle; Ulrich Luxemburger; Alexandra Kemmer-Brück; David Langer; Martin Bexon; Stefanie Bolte; Katalin Karikó; Tania Palanche; Boris Fischer; Armin Schultz; Pei-Yong Shi; Camila Fontes-Garfias; John L Perez; Kena A Swanson; Jakob Loschko; Ingrid L Scully; Mark Cutler; Warren Kalina; Christos A Kyratsous; David Cooper; Philip R Dormitzer; Kathrin U Jansen; Özlem Türeci
Journal:  Nature       Date:  2020-09-30       Impact factor: 49.962
  5 in total
  9 in total

1.  Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review.

Authors:  Verdiana Caironi; Fabián Pitoia; Pierpaolo Trimboli
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

2.  Orbital inflammatory disease following mRNA SARS-CoV-2 vaccine.

Authors:  Solange Grunenwald; Gabriel Lethellier; Philippe Imbert; Céline Dekeister; Philippe Caron
Journal:  Clin Case Rep       Date:  2022-06-07

3.  Re: "Thyroid Eye Disease Following COVID-19 Vaccine in a Patient With a History Graves' Disease: A Case Report".

Authors:  Won Sriwijitalai; Viroj Wiwanitkit
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2022 Jan-Feb 01       Impact factor: 1.746

Review 4.  Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence.

Authors:  A Jafarzadeh; M Nemati; S Jafarzadeh; P Nozari; S M J Mortazavi
Journal:  J Endocrinol Invest       Date:  2022-03-26       Impact factor: 5.467

5.  A Case of Graves' Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature.

Authors:  Dalia Cuenca; Mercedes Aguilar-Soto; Moisés Mercado
Journal:  Eur J Case Rep Intern Med       Date:  2022-04-14

6.  New-onset Graves' disease following SARS-CoV-2 vaccination: a case report.

Authors:  Ringo Manta; Charlotte Martin; Vinciane Muls; Kris G Poppe
Journal:  Eur Thyroid J       Date:  2022-07-19

Review 7.  Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns.

Authors:  Dimitra S Mouliou; Efthimios Dardiotis
Journal:  Diagnostics (Basel)       Date:  2022-06-26

Review 8.  Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management.

Authors:  Philippe Caron
Journal:  Endocrine       Date:  2022-06-28       Impact factor: 3.925

9.  Graves' disease following vaccination against SARS-CoV-2: A systematic review of the reported cases.

Authors:  Konstantinos Katsikas Triantafyllidis; Panagiotis Giannos; Dimitra Stathi; Konstantinos S Kechagias
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.